Merck at Morgan Stanley healthcare conference: pipeline gains build

Merck said its more-than-$70 billion mid-2030s revenue target from recent launches and pipeline assets now appears conservative, with a potential increase under consideration as soon as the start of 2027. Positive and earlier-than-expected Phase III developments for the Moderna-partnered INT melanoma therapy and sacituzumab tirumotecan, plus upside from the Terns acquisition and MK-2010, strengthen the pipeline outlook; oncology alone is projected to contribute more than $25 billion. Management also highlighted newly approved oral PCSK9 inhibitor enlicitide, which can reduce LDL by up to 60% and targets roughly 30 million U.S. lipid-treated patients not at goal, although broad commercial coverage is not expected until end-2027 and Medicare coverage by 2028.

Analysis

MRK’s re-rating hinges less on a future revision to its aggregate pipeline target than on whether investors begin to underwrite a credible post-KEYTRUDA earnings bridge. The fall INT dataset is the nearer-term valuation catalyst: robust recurrence-free-survival magnitude and clean tolerability would validate a platform with unusually high strategic value because it extends MRK’s entrenched oncology channel rather than requiring a standalone commercial build. MRNA is the higher-beta read-through, but its economics remain constrained by profit-sharing and its valuation will be more sensitive to proof that individualized cancer vaccines can replicate beyond melanoma.

The oral PCSK9 launch should not be modeled as a rapid blockbuster until formulary placement and persistence data emerge. A low-net-price strategy can expand treated patients but initially dilutes gross-to-net economics and raises the risk that payers use the product to force larger rebates from AMGN’s Repatha and NVS’s Leqvio; the disruptive outcome is category price compression rather than immediate share capture. The relevant 1-3 month datapoints are commercial coverage wins, abandonment rates, refill persistence and any CMS quality-measure movement—not early prescription anecdotes.

In ADCs, MRK’s key advantage is portfolio optionality: a positive combination signal could protect its oncology franchise as PD-1 monotherapy matures, while AZN’s upcoming Dato-DXd data can reset the competitive bar in lung cancer before MRK has mature global comparative evidence. Consensus may be assigning too much value to the number of ongoing studies and too little to payload-specific toxicity, biomarker selection and combination discontinuation rates. A meaningful pipeline-target increase is therefore more likely a sentiment catalyst than an earnings catalyst until individual asset timelines, probabilities and launch investments are disclosed.

The principal 6-18 month risk is capital-allocation drift: an improved external-deal process is not independently verifiable, and higher confidence can encourage acquisitions at peak biotech valuations. Falsify the constructive MRK thesis if INT’s full data show weak absolute benefit or safety friction, ADC combinations fail to differentiate against AZN, or 2027 launch guidance implies incremental SG&A and rebates are outrunning new-product revenue.

Key Decisions for Investors

• Maintain/add MRK on weakness ahead of the fall INT presentation; use a 6-9 month horizon. Risk/reward is favorable only if the position is sized as a clinical-data trade: take profits on a material pre-data run and reduce if full INT data fail to show durable, clinically meaningful separation rather than merely statistical success.
• Pair long MRK / short AZN over the next 3-6 months only after reviewing AZN’s Dato-DXd readout. Enter the pair if AZN data reveal biomarker restriction, tolerability limitations or weak all-comer efficacy; avoid pre-committing because a broad AZN success would directly weaken the relative ADC differentiation thesis.
• Treat MRNA as an event-driven satellite long into the INT presentation rather than a clean MRK substitute. Use defined-risk calls or a small cash position; exit on evidence that benefit is confined to melanoma, since cross-tumor platform optionality is the central upside driver.
• Do not underwrite enlicitide revenue acceleration until quarterly evidence shows formulary breadth, refill persistence and net-price realization. Establish an alert around 2027 commercial-access milestones; if uptake is strong but net pricing deteriorates, prefer AMGN/NVS as more defensive category exposures rather than extrapolating MRK volume into earnings.